Group 1: Company Overview and Mission - The company focuses on developing biotechnology to benefit human health, with a mission centered around innovative biological technology for early disease screening, diagnosis, and treatment solutions [1] - The main products include in vitro diagnostic reagents and instruments, with a strategic emphasis on biopharmaceuticals through incubation and equity participation [1] Group 2: Financial Performance - In the third quarter, the company achieved a revenue of CNY 282.92 million, representing a year-on-year growth of 37.48% [1] - The net profit attributable to shareholders for the same period was CNY 1.37 million, showing a significant increase of 109.31% compared to the previous year [1] Group 3: Product Applications - The company's products are widely used in the detection of diseases such as hepatitis, liver cancer, cardiovascular diseases, diabetes, and tumors, with successful promotion in primary healthcare markets [1] - The innovative products, including AFP-L3% and DCP, have been applied in major hospitals across the country [1] Group 4: Shareholder Engagement and Value Management - The company has implemented a share repurchase plan for 2024, utilizing its own funds to buy back A-shares, with a total expenditure of CNY 258 million for repurchasing 575.45 million shares, accounting for 6.22% of total shares [3] - The company emphasizes value investment and aims to enhance its intrinsic investment value while improving communication with investors [3] Group 5: Technological Advancements - The company has developed an automated detection platform for exosome miRNA, which combines innovative capture technology and precise detection methods for early disease diagnosis [4] - This dual-technology approach has shown significant potential in early screening for various cancers and neurodegenerative diseases [4] Group 6: Competitive Advantages - The company has 19 years of experience in in vitro diagnostics, with leading products in hepatitis and liver cancer diagnosis, as well as Alzheimer's and neurodegenerative diseases [4] - It offers a comprehensive range of diagnostic instruments suitable for various clinical settings, from small to high-throughput automated systems [4]

证券代码：688068 证券简称：热景生物 公告编号：2024-072 北京热景生物技术股份有限公司 关于召开 2024 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： https://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 投资者可于 2024 年 11 月 07 日(星期四) 至 11 月 13 日(星期三)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 hotgen@hotgen.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 北京热景生物技术股份有限公司（以下简称"公司"）已于 2024 年 10 月 31 日发布公司 2024 年第三季度报告，为便于广大投资者更全面深入地了解公 司 2024 年第三季度经营成果、财务状况，公司计划于 2024 年 11 月 14 日下午 14:00-15:00 举行 2024 年第三季度业绩说明会，就投资者关心的问题进行交 流。 二、 说明会 ...

Revenue and Profit Performance - Revenue for the third quarter was RMB 137.35 million, a 37.48% increase year-over-year[2] - Net profit attributable to shareholders for the third quarter was RMB 2.83 million, a 109.31% increase year-over-year[2] - Cumulative revenue from the beginning of the year to the end of the reporting period was RMB 386.16 million, a 5.10% decrease year-over-year[2] - Cumulative net profit attributable to shareholders from the beginning of the year to the end of the reporting period was a loss of RMB 40.64 million, a 174.73% decrease year-over-year[2] - Total revenue for the first three quarters of 2024 was RMB 386,162,937.71, a decrease of 5.1% compared to RMB 406,916,772.66 in the same period of 2023[15] - Net profit for the first three quarters of 2024 was a loss of RMB 42,681,396.61, compared to a profit of RMB 46,935,484.85 in the same period of 2023[16] - Basic earnings per share for the first three quarters of 2024 was a loss of RMB 0.44, compared to a profit of RMB 0.61 in the same period of 2023[17] R&D and Sales Expenses - R&D investment for the third quarter was RMB 27.55 million, a 11.27% decrease year-over-year[4] - R&D investment as a percentage of revenue for the third quarter was 20.06%, a decrease of 11.02 percentage points year-over-year[4] - R&D expenses for the first three quarters of 2024 were RMB 77,198,837.52, a decrease of 22.1% compared to RMB 99,168,834.05 in the same period of 2023[15] - Sales expenses for the first three quarters of 2024 were RMB 129,084,145.72, a slight decrease of 1.3% compared to RMB 130,802,159.01 in the same period of 2023[15] Assets and Liabilities - Total assets at the end of the reporting period were RMB 3.41 billion, a 4.50% decrease compared to the end of the previous year[4] - Equity attributable to shareholders at the end of the reporting period was RMB 3.26 billion, a 3.20% decrease compared to the end of the previous year[4] - The company's total assets are 3,410,785,297.56, compared to 3,571,560,503.77 in the previous period[13] - Total liabilities as of the end of Q3 2024 were RMB 150,833,300.36, a decrease of 26.8% compared to RMB 206,016,985.86 at the end of Q3 2023[14] - Total equity attributable to the parent company as of the end of Q3 2024 was RMB 3,259,592,370.91, a decrease of 3.2% compared to RMB 3,367,489,040.66 at the end of Q3 2023[14] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period is 11,183[10] - Lin Changqing holds 21,682,487 shares, accounting for 23.45% of the total shares[10] - Zhou Xin holds 6,806,629 shares, accounting for 7.36% of the total shares[10] - Qingdao Tongcheng Rejing Enterprise Management Consulting Partnership holds 4,211,357 shares, accounting for 4.55% of the total shares[10] Cash Flow and Financial Activities - Operating cash flow for the quarter was -9.57 million RMB, a significant decline compared to the previous period[19] - Investment cash flow showed a net outflow of 126.53 million RMB, indicating increased investment activities[19] - Financing cash flow had a net outflow of 67.37 million RMB, primarily due to dividend payments and other financing-related expenses[20] - Total cash and cash equivalents decreased by 203.37 million RMB, ending the quarter at 72.74 million RMB[20] - Cash received from tax refunds increased to 12.65 million RMB, up from 4.94 million RMB in the previous period[19] - Cash received from other operating activities dropped significantly to 6.61 million RMB from 62.20 million RMB[19] - Cash paid for goods and services decreased to 139.32 million RMB from 318.54 million RMB, reflecting reduced operational expenses[19] - Cash paid to employees decreased to 152.34 million RMB from 287.75 million RMB, indicating potential cost optimization[19] - Cash received from investments increased to 179.69 million RMB, up from 934.73 million RMB, showing a shift in investment strategy[19] - Cash paid for investments rose to 258.20 million RMB, up from 691.29 million RMB, suggesting increased capital allocation towards investments[19] Non-Recurring Items and Business Growth - Non-recurring gains and losses for the third quarter amounted to RMB 27.56 million[7] - The increase in revenue for the third quarter was mainly due to growth in non-COVID-related business[8] Current and Non-Current Assets - The company's monetary funds amount to 72,745,774.79, with a significant increase to 276,112,073.85[12] - The company's total current assets are 1,265,944,743.09, compared to 840,146,256.91 in the previous period[12] - The company's total non-current assets are 2,144,840,554.47, compared to 2,731,414,246.86 in the previous period[13] - The company's accounts payable amount to 82,118,937.63, compared to 118,194,698.61 in the previous period[13] - The company's contract liabilities amount to 16,816,089.03, compared to 28,086,503.10 in the previous period[13] Cash Flow from Operations - Cash received from sales of goods and services in the first three quarters of 2024 was RMB 361,466,766.89, a decrease of 2.4% compared to RMB 370,393,706.16 in the same period of 2023[18]

证券代码：688068 证券简称：热景生物 公告编号：2024-070 北京热景生物技术股份有限公司 关于子公司近期获得资质情况的自愿披露公告 一、获得资质的具体情况 （一） 获得国内医疗器械注册证情况 | 序号 | 产品名称 | | 注册证号 | 类别 | 发证日期 | 有效期至 | 发证机构 | | --- | --- | --- | --- | --- | --- | --- | --- | | 1 | 实时荧光定量 | PCR | 国械注准 | III | 2024/10/11 | 2029/10/10 | 国家药品监督 | | | 分析仪 | | 20243222018 | | | | 管理局 | 二、对公司的影响 上述资质的取得，丰富了公司产品的种类，进一步完善了公司体外诊断产品 的菜单，便于进一步提高公司的市场拓展能力，提升公司核心竞争力。 三、风险提示 上述产品的实际销售情况取决于市场的推广效果、同类竞争产品的销售以及 产品需求等多重因素影响，具有较大的不确定性。敬请广大投资者注意投资风险。 公司将继续加大对产品的研发投入，不断向市场推出对人类健康和生命有显著价 值的产品，全力以赴做好公司经营 ...

北京热景生物技术股份有限公司 关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）近期获得境外资质认证 6 项。相关信息如下： 一、获得资质的具体情况 证券代码：688068 证券简称：热景生物 公告编号：2024-069 1 | 盒（磁微粒化学发光 | Hormone test | RI AKL | | --- | --- | --- | | 免疫分析法） | (Chemiluminescence | 20101421300 | | | Immunoassay) | | 二、对公司的影响 上述资质的取得，丰富了公司产品的种类，进一步完善了公司体外诊断产品 的菜单，同时积极响应了海外市场的需求，便于进一步提高公司的市场拓展能力， 提升公司核心竞争力。 三、风险提示 上述产品的实际销售情况取决于市场的推广效果、同类竞争产品的销售以及 产品需求等多重因素影响，具有较大的不确定性。敬请广大投资者注意投资风险。 公司将继续加大对产品的研发 ...

北京热景生物技术股份有限公司 投资者关系活动记录表 证券简称：热景生物 证券代码：688068 编号：2024-003 | --- | --- | --- | --- | |----------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------|------------------------------- ...

证券代码：688068 证券简称：热景生物 公告编号：2024-068 一、募集资金基本情况 依据中国证券监督管理委员会出具《关于同意北京热景生物技术股份有限公 司首次公开发行股票注册的批复》（证监许可〔2019〕1615 号），同意公司向 社会公开发行人民币普通股 1,555.00 万股，发行价格为 29.46 元/股，共计募集资 金人民币 45,810.30 万元，扣除发行费用（包括保荐费、承销费、审计及验资费、 律师费、信息披露费、发行手续费等）合计人民币 5,903.21 万元（不含增值税） 后，实际募集资金净额为人民币 39,907.09 万元。上述募集资金已于 2019 年 9 月 24 日全部到位，并由容诚会计师事务所（特殊普通合伙）于 2019 年 9 月 25 日对本次发行募集资金的到账情况进行了审验，并出具了会验字[2019]7401 号 《验资报告》。 二、募集资金专户存放及专户管理情况 根据有关法律法规及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》的规定，遵循规范、安全、高效、透明的原则，公司制定了《北 京热景生物技术股份有限公司募集资金管理制度》，对募集资金的存 ...

中国国际金融股份有限公司 关于北京热景生物技术股份有限公司股东 向特定机构投资者询价转让股份的核查报告 上海证券交易所： 中国国际金融股份有限公司（以下简称"中金公司"）受北京热景生物技术 股份有限公司（以下简称"热景生物"）股东周锌（以下亦称"转让方"）委托， 担任本次热景生物股东向特定机构投资者询价转让（以下简称"本次询价转让"） 的组织券商。 经核查，中金公司就本次询价转让的股东、受让方是否符合《上海证券交 易所科创板上市公司自律监管指引第 4 号——询价转让和配售》（以下简称 "《询价转让和配售指引》"）要求，本次询价转让的询价、转让过程与结果是 否公平、公正，是否符合《询价转让和配售指引》的规定作出如下报告说明。 1 （三）转让方式 转让方作为上海证券交易所科创板上市公司热景生物首发前股东，根据 《询价转让和配售指引》有关规定以向特定机构投资者询价转让方式转让股份。 （四）本次询价转让价格下限确定原则 股东与组织券商综合考虑股东自身资金需求等因素，协商确定本次询价转 让的价格下限。本次询价转让价格下限不低于中金公司向投资者发送《股东以 向特定机构投资者询价转让方式减持北京热景生物技术股份有限公司首发 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-067 北京热景生物技术股份有限公司 股东询价转让结果报告书暨持股5%以上 股东权益变动达到1%的提示性公告 周锌保证向北京热景生物技术股份有限公司（以下简称"公司"）提供的信息 内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其真实性、准确性和完 整性依法承担法律责任。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 重要内容提示: 周锌通过本次询价转让减持公司股份 1,000,000 股，占公司总股本的 1.08%。 此外，周锌于 2021 年 7 月 2 日至 2021 年 7 月 13 日期间通过集中竞价方式减持公 司股份 482,333 股，占公司总股本的 0.78%。同时，因公司资本公积转增股本，周 锌持股数量增加；因限制性股票归属，公司总股本增加，周锌持股比例被动稀释 0.04%。综上权益变动比例累计超过 1%, 周锌持股比例由 9.26%减少至 7.36% 一、 转让方情况 (一)转让方基本情况 截至 2024 年 8 月 30 日，转让方所持公司股份的数量、比例情况如下： 本次询价转让的价格为 21.46 ...

证券代码：688068 证券简称：热景生物 公告编号：2024-065 北京热景生物技术股份有限公司 关于公司及子公司近期获得资质情况的自愿披露 公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京热景生物技术股份有限公司（以下简称"公司"）近期获得国内医疗器械 注册证 3 项，获得境外资质认证 29 项。相关信息如下： 一、获得资质的具体情况 2 | | （磁微粒化学发光免 | (Chemiluminescence | R000 | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | | 疫分析法） | Immunoassay) | | | | | | | 16 | 睾酮测定试剂盒（磁 微粒化学发光免疫分 | Testosterone test (Chemiluminescence | IVDR 781093 | Class B | 2024/9/6 | 2029/5/30 | 欧盟 | | | 析法） | Immunoassay) | R000 ...